Skip to content

Net Income at other companies

Immunome logo
ImmunomeIMNM
-$53.84M-29.3%
CTO
Citius Oncology, Inc.CTOR
-$26.61M-244%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$19.63M-49.3%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$632.78M-388%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$128M-14.3%

Segments

By segment

See full
Chief Operating Decision Maker-$10.4M-168%

Other financials

Income statement

See full
Operating income-$10.2M-103%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K
Free cash flow-$3.7M

Valuation

See full
Market cap$84.62M+66.4%
Enterprise value$103.7M

Returns & leverage

See full
Return on equity470%
Debt / equity-1.8×
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's net income?
OS Therapies (OSTX) reported net income of -$10.4M in Q1 2026.
How has OS Therapies's net income changed year-over-year?
OS Therapies's net income decreased by 168.2% year-over-year, from -$3.88M to -$10.4M.
What is the long-term trend for OS Therapies's net income?
Over 2 years (2023 to 2025), OS Therapies's net income has grown at a 92.1% compound annual growth rate (CAGR), from -$7.79M to -$28.75M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.